

www.FirstRanker.com www.FirstRanker.com

GUJARAT TECHNOLOGICAL UNIVERSITY

B.PHARM - SEMESTER- 8 EXAMINATION - WINTER -2019

Subject Code: 2280001	Date: 14-11-2019

Subject Name: Dosage form Design II

Time: 02:30 PM TO 05:30 PM **Total Marks: 80**

Instructions:

1. Attempt any five questions.

- 2. Make suitable assumptions wherever necessary.
- 3. Figures to the right indicate full marks.

Q.1	(a) (b)	Discus controlled release formulation with suitable example. Explain Hixson and Crowell's cube root law of dissolution.	06 05
	(c)	Give the difference between conventional and controlled release system, describe the evaluation of oral controlled drug delivery system.	05
Q.2	(a) (b)	Discuss formulation of osmotic based drug delivery system. Enlist parameters to be considered in design of CRDDS.Discusss approaches for oral delayed release DDS.	06 05
	(c)	Give account of polymers used in formulation of colon drug delivery system.	05
Q.3	(a)	Discuss Penetration enhancer in TDDS.	06
	(b) (c)	Discuss in detail formulation of transdermal drug delivery system. Discuss in vitro drug release and permeation studies for TDDS.	05 05
Q.4	(a) (b)	Discuss method of preparation of nano particles. Discuss over view of anatomy and physiology of eye and explain absorption pathway for drug in eye.	06 05
	(c)	Give an account of approaches for designing of gastro retentive dosage form.	05
Q.5	(a) (b)	Discuss on Wagner nelson and Loo-Riegelman method. Note on volume of distributions. Discuss one compartment open model, I.V. infusion model and discuss the effect	06 05 05
	(c)	of loading IV injection dose. Describe the derivation of various pharmacokinetic parameters for the model.	US
Q. 6	(a) (b)	Explain Michaelis Menten kinetics and method to determine Km and Vmax. What are pharmacokinetic model? Explain in detail compartment model?	06 05
	(c)	Define clearance, total body clearance and organ clearance .what is extraction ratio?	05
Q.7	(a)	Explain dosage adjustment in patients with renal and hepatic failure.	06
	(b)	What are the various ways of reducing risk of drug interaction?	05
	(c)	Define clinical pharmacokinetics and describe its scope.	05
